| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | marinopyrrole A | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |